首页> 外文OA文献 >Enantiopure Indolo2,3-aquinolizidines: Synthesis and Evaluation as NMDA Receptor Antagonists
【2h】

Enantiopure Indolo2,3-aquinolizidines: Synthesis and Evaluation as NMDA Receptor Antagonists

机译:对映体吲哚2,3-a喹诺唑烷类化合物:NMDA受体拮抗剂的合成与评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Enantiopure tryptophanol is easily obtained from the reduction of its parent natural amino acid trypthophan (available from the chiral pool), and can be used as chiral auxiliary/inductor to control the stereochemical course of a diastereoselective reaction. Furthermore, enantiopure tryptophanol is useful for the syntheses of natural products or biological active molecules containing the aminoalcohol functionality. In this communication, we report the development of a small library of indolo[2,3-a]quinolizidines and evaluation of their activity as N-Methyl D-Aspartate (NMDA) receptor antagonists. The indolo[2,3-a]quinolizidine scaffold was obtained using the following key steps: (i) a stereoselective cyclocondensation of (S)- or (R)-tryptophanol with appropriate racemic -oxoesters; (ii) a stereocontrolled cyclization on the indole nucleus. The synthesized enantiopure indolo[2,3-a]quinolizidines were evaluated as NMDA receptor antagonists and one compound was identified to be 2.9-fold more potent as NMDA receptor blocker than amantadine (used in the clinic for Parkinson's disease). This compound represents a hit compound for the development of novel NMDA receptor antagonists with potential applications in neurodegenerative disorders associated with overactivation of NMDA receptors.
机译:对映体色氨酸可以很容易地通过还原其母体天然氨基酸色氨酸(可从手性库中获得)而获得,并且可以用作手性助剂/诱导剂来控制非对映选择性反应的立体化学过程。此外,对映纯色氨酸可用于合成天然产物或含有氨基醇官能团的生物活性分子。在本次交流中,我们报告了一个吲哚[2,3-a]喹喔啉小文库的开发以及它们作为N-甲基D-天冬氨酸(NMDA)受体拮抗剂的活性的评估。使用以下关键步骤获得吲哚并[2,3-a]喹喔啉骨架:(i)(S)-或(R)-色氨酸与适当的外消旋-氧酸酯的立体选择性环缩合; (ii)在吲哚核上的立体控制环化。合成的对映体纯的吲哚[2,3-a]喹诺唑烷被评估为NMDA受体拮抗剂,并且一种化合物被鉴定为比NMADA(在帕金森氏病临床中使用)更有效地作为NMDA受体阻滞剂。该化合物代表开发新型NMDA受体拮抗剂的热门化合物,在与NMDA受体过度活化有关的神经退行性疾病中具有潜在的应用前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号